Drugs / [18F]Fluoropropyl-Trimethoprim
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07343934 | May 2026 → Nov 2027 expected | B-cell neoplasm | University of Pennsylvania | Recruiting | No outcome recorded |
| Phase 1 | NCT04263792 | Feb 2020 → Jul 2026 overdue | bacterial infectious disease | University of Pennsylvania | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | [18F]fluoropropyl-trimethoprim | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04263792 ↗ |
| Known as | [18F]F-TMP | “\[18F\]Fluoropropyl-Trimethoprim, also known as \[18F\]F-TMP, is a radiolabeled imaging agent for positron emission tomography (PET/CT).” NCT04263792 ↗ |
| Modality | Diagnostic / imaging agent | “is a radiolabeled imaging agent for positron emission tomography (PET/CT).” NCT04263792 ↗ |
| Route | Other | “is injected into the body” NCT04263792 ↗ |